Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-20-32834200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees22
Next Earnings DateN/A
OptionableOptionable
Verona Pharma (LON:VRP) Frequently Asked Questions
What is Verona Pharma's stock symbol?
Verona Pharma trades on the London Stock Exchange (LON) under the ticker symbol "VRP."
How were Verona Pharma's earnings last quarter?
Verona Pharma Plc (LON:VRP) announced its quarterly earnings data on Tuesday, May, 8th. The company reported ($14.50) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($23.70) by $9.20. View Verona Pharma's Earnings History.
What is the consensus analysts' recommendation for Verona Pharma?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verona Pharma.
Has Verona Pharma been receiving favorable news coverage?
News coverage about VRP stock has been trending positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Verona Pharma earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are some of Verona Pharma's key competitors?
Some companies that are related to Verona Pharma include Enochian Biosciences (ENOB), BELLUS Health (BLU), OncoCyte (OCX), OncoCyte (OCX), Pfenex (PFNX), Rafael (RFL), IMV (IMV), MediGene (MDG1), Bioventix (BVXP), Arix Bioscience (ARIX), CorMedix (CRMD), CorMedix (CRMD), BioTime (BTX), BioTime (BTX) and CEL-SCI (CVM).
What other stocks do shareholders of Verona Pharma own?
Who are Verona Pharma's key executives?
Verona Pharma's management team includes the folowing people:
- Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)
- Mr. Piers John Morgan, Chief Financial Officer (Age 53)
- Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)
- Ms. Victoria Stewart, Director of Communications
- Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57)
How do I buy shares of Verona Pharma?
Shares of VRP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Verona Pharma's stock price today?
One share of VRP stock can currently be purchased for approximately GBX 58.50.
How big of a company is Verona Pharma?
Verona Pharma has a market capitalization of £61.65 million. Verona Pharma employs 22 workers across the globe.
What is Verona Pharma's official website?
How can I contact Verona Pharma?
Verona Pharma's mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200.
MarketBeat Community Rating for Verona Pharma (LON VRP)
MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote "Outperform" if you believe VRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
